These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23330908)

  • 1. Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
    Feng E; Shin WJ; Zhu X; Li J; Ye D; Wang J; Zheng M; Zuo JP; No KT; Liu X; Zhu W; Tang W; Seong BL; Jiang H; Liu H
    J Med Chem; 2013 Feb; 56(3):671-84. PubMed ID: 23330908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
    Ye D; Shin WJ; Li N; Tang W; Feng E; Li J; He PL; Zuo JP; Kim H; Nam KY; Zhu W; Seong BL; No KT; Jiang H; Liu H
    Eur J Med Chem; 2012 Aug; 54():764-70. PubMed ID: 22795831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities.
    Lin CH; Chang TC; Das A; Fang MY; Hung HC; Hsu KC; Yang JM; von Itzstein M; Mong KK; Hsu TA; Lin CC
    Org Biomol Chem; 2013 Jun; 11(24):3943-8. PubMed ID: 23695381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
    Wen WH; Wang SY; Tsai KC; Cheng YS; Yang AS; Fang JM; Wong CH
    Bioorg Med Chem; 2010 Jun; 18(11):4074-84. PubMed ID: 20452227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors.
    Das A; Adak AK; Ponnapalli K; Lin CH; Hsu KC; Yang JM; Hsu TA; Lin CC
    Eur J Med Chem; 2016 Nov; 123():397-406. PubMed ID: 27487569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity.
    Shie JJ; Fang JM; Lai PT; Wen WH; Wang SY; Cheng YS; Tsai KC; Yang AS; Wong CH
    J Am Chem Soc; 2011 Nov; 133(44):17959-65. PubMed ID: 21942552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities.
    Li J; Zheng M; Tang W; He PL; Zhu W; Li T; Zuo JP; Liu H; Jiang H
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5009-13. PubMed ID: 16876409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
    Mai BK; Li MS
    Biochem Biophys Res Commun; 2011 Jul; 410(3):688-91. PubMed ID: 21693105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs.
    Dholakia D; Goyal S; Jamal S; Singh A; Das A; Grover A
    BMC Bioinformatics; 2016 Dec; 17(Suppl 19):512. PubMed ID: 28155702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
    Magano J
    Chem Rev; 2009 Sep; 109(9):4398-438. PubMed ID: 19537777
    [No Abstract]   [Full Text] [Related]  

  • 11. Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors.
    Liu Y; Zhang L; Gong J; Fang H; Liu A; Du G; Xu W
    J Enzyme Inhib Med Chem; 2011 Aug; 26(4):506-13. PubMed ID: 21143042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors.
    Cheng LP; Wang TC; Yu R; Li M; Huang JW
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3622-3629. PubMed ID: 30389293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
    Bromba CM; Mason JW; Brant MG; Chan T; Lunke MD; Petric M; Boulanger MJ; Wulff JE
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7137-41. PubMed ID: 22001088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
    Smith PW; Sollis SL; Howes PD; Cherry PC; Starkey ID; Cobley KN; Weston H; Scicinski J; Merritt A; Whittington A; Wyatt P; Taylor N; Green D; Bethell R; Madar S; Fenton RJ; Morley PJ; Pateman T; Beresford A
    J Med Chem; 1998 Mar; 41(6):787-97. PubMed ID: 9526555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
    Liu KC; Lee PS; Wang SY; Cheng YS; Fang JM; Wong CH
    Bioorg Med Chem; 2011 Aug; 19(16):4796-802. PubMed ID: 21778065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different Inhibitory Potencies of Oseltamivir Carboxylate, Zanamivir, and Several Tannins on Bacterial and Viral Neuraminidases as Assessed in a Cell-Free Fluorescence-Based Enzyme Inhibition Assay.
    Quosdorf S; Schuetz A; Kolodziej H
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29149072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.
    Schade D; Kotthaus J; Riebling L; Kotthaus J; Müller-Fielitz H; Raasch W; Hoffmann A; Schmidtke M; Clement B
    J Pharm Sci; 2015 Sep; 104(9):3208-19. PubMed ID: 26037932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical insight into the emergence of influenza virus strains that are resistant to Relenza.
    Shidmoossavee FS; Watson JN; Bennet AJ
    J Am Chem Soc; 2013 Sep; 135(36):13254-7. PubMed ID: 24001125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors.
    Liu Y; Jing F; Xu Y; Xie Y; Shi F; Fang H; Li M; Xu W
    Bioorg Med Chem; 2011 Apr; 19(7):2342-8. PubMed ID: 21382719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors.
    Ju H; Zhang J; Sun Z; Huang Z; Qi W; Huang B; Zhan P; Liu X
    Eur J Med Chem; 2018 Feb; 146():220-231. PubMed ID: 29407952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.